CEMI - Chembio +16% as it expects FDA test approval January, 02 2020 05:44 PM Chembio Diagnostics Inc. Chembio Diagnostics (NASDAQ:CEMI) is up 15.8% after hours following its update on an FDA submission of its DPP HIV-Syphilis test.More news on: Chembio Diagnostics, Inc., Healthcare stocks news, Stocks on the move, Read more ...